IL252604B - Chimeric antigen receptors and methods of use - Google Patents

Chimeric antigen receptors and methods of use

Info

Publication number
IL252604B
IL252604B IL252604A IL25260417A IL252604B IL 252604 B IL252604 B IL 252604B IL 252604 A IL252604 A IL 252604A IL 25260417 A IL25260417 A IL 25260417A IL 252604 B IL252604 B IL 252604B
Authority
IL
Israel
Prior art keywords
misuse
chimeric antigen
antigen receptors
receptors
chimeric
Prior art date
Application number
IL252604A
Other languages
English (en)
Hebrew (he)
Other versions
IL252604A0 (en
Inventor
Kisielow Jan
Obermair Franz-Josef
Kopf Manfred
Original Assignee
Eth Zuerich
Kisielow Jan
Franz Josef Obermair
Kopf Manfred
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eth Zuerich, Kisielow Jan, Franz Josef Obermair, Kopf Manfred filed Critical Eth Zuerich
Publication of IL252604A0 publication Critical patent/IL252604A0/en
Publication of IL252604B publication Critical patent/IL252604B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL252604A 2014-12-19 2017-06-01 Chimeric antigen receptors and methods of use IL252604B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14199148 2014-12-19
PCT/EP2015/080576 WO2016097334A1 (en) 2014-12-19 2015-12-18 Chimeric antigen receptors and methods of use

Publications (2)

Publication Number Publication Date
IL252604A0 IL252604A0 (en) 2017-07-31
IL252604B true IL252604B (en) 2021-02-28

Family

ID=52292645

Family Applications (1)

Application Number Title Priority Date Filing Date
IL252604A IL252604B (en) 2014-12-19 2017-06-01 Chimeric antigen receptors and methods of use

Country Status (10)

Country Link
US (3) US10865408B2 (de)
EP (2) EP3851450B1 (de)
JP (1) JP6718450B2 (de)
CN (1) CN107995926B (de)
AU (1) AU2015366305B2 (de)
CA (2) CA2969056C (de)
DK (1) DK3233903T3 (de)
ES (2) ES2999411T3 (de)
IL (1) IL252604B (de)
WO (1) WO2016097334A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
SG10201912301XA (en) 2013-11-04 2020-02-27 Uti Lp Methods and compositions for sustained immunotherapy
AU2015366305B2 (en) 2014-12-19 2020-03-05 ETH Zürich Chimeric antigen receptors and methods of use
HK1252348A1 (zh) 2015-05-06 2019-05-24 Uti Limited Partnership 用於持续疗法的纳米颗粒组合物
WO2017004252A1 (en) * 2015-06-30 2017-01-05 The Arizona Board Of Regents On Behalf Of The University Of Arizona Redirected cells with mhc chimeric receptors and methods of use in immunotherapy
EP3607058A4 (de) * 2017-04-07 2020-12-16 UTI Limited Partnership Test zur messung der wirksamkeit von rezeptorligandwechselwirkungen in nanomedikamenten
CN111315769A (zh) * 2017-09-06 2020-06-19 加州理工学院 信号传导和抗原呈递双功能受体(sabr)
EP3716949A4 (de) 2017-11-29 2022-05-18 UTI Limited Partnership Verfahren zur behandlung von autoimmunerkrankungen
CN120028543A (zh) * 2018-04-12 2025-05-23 苏黎世联邦理工学院 作为疫苗设计的表位选择工具的哺乳动物mhc肽展示
WO2020037046A1 (en) * 2018-08-14 2020-02-20 Board Of Regents, The University Of Texas System Single molecule sequencing peptides bound to the major histocompatibility complex
US20210324037A1 (en) * 2018-10-19 2021-10-21 ETH Zürich Chimeric molecules
CN111676195A (zh) * 2019-03-11 2020-09-18 北京卡替医疗技术有限公司 一种治疗t细胞肿瘤的ucar免疫细胞
CA3263470A1 (en) 2022-07-29 2024-02-01 Repertoire Immune Medicines Inc T-LYMPHOCYTE EPITOPES ASSOCIATED WITH TYPE 1 DIABETES
WO2025072849A1 (en) 2023-09-29 2025-04-03 Repertoire Immune Medicines, Inc. Mhc-presentable peptides associated with type 1 diabetes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001261624A1 (en) * 2000-05-25 2001-12-03 Altor Bioscience Corporation Modulation of t-cell receptor interactions
US20080286312A1 (en) 2002-06-12 2008-11-20 Gavish-Galilee Bio Applications Ltd. Membrane-anchored beta2 microglobulincovalently linked to MHC class I peptide epitopes
PL2618835T3 (pl) * 2010-09-20 2017-12-29 Biontech Cell & Gene Therapies Gmbh Swoiste względem antygenu receptory komórek T i epitopy dla komórek T
HK1211039A1 (en) * 2012-07-27 2016-05-13 The Board Of Trustees Of The University Of Illinois Engineering t-cell receptors
AU2014216130B2 (en) * 2013-02-15 2017-11-16 The Regents Of The University Of California Chimeric antigen receptor and methods of use thereof
AU2015366305B2 (en) 2014-12-19 2020-03-05 ETH Zürich Chimeric antigen receptors and methods of use

Also Published As

Publication number Publication date
CN107995926A (zh) 2018-05-04
ES2857052T3 (es) 2021-09-28
AU2015366305B2 (en) 2020-03-05
EP3851450A1 (de) 2021-07-21
US11939572B2 (en) 2024-03-26
DK3233903T3 (da) 2021-02-22
EP3851450B1 (de) 2024-11-27
JP2017537642A (ja) 2017-12-21
JP6718450B2 (ja) 2020-07-08
US20210123042A1 (en) 2021-04-29
EP3233903A1 (de) 2017-10-25
CN107995926B (zh) 2021-07-06
EP3233903B1 (de) 2020-12-09
CA2969056A1 (en) 2016-06-23
CA3207135A1 (en) 2016-06-23
EP3851450C0 (de) 2024-11-27
CA2969056C (en) 2023-09-05
IL252604A0 (en) 2017-07-31
US10865408B2 (en) 2020-12-15
US20240425847A1 (en) 2024-12-26
WO2016097334A1 (en) 2016-06-23
AU2015366305A1 (en) 2017-07-27
US20190345485A1 (en) 2019-11-14
ES2999411T3 (en) 2025-02-25

Similar Documents

Publication Publication Date Title
IL281819A (en) Chimeric antigen receptors and methods of making
IL251030B (en) Chimeric antigen receptors
IL252295A0 (en) Chimeric antigen receptors and methods of using them
IL254068A0 (en) Anti-dll3 chimeric antigen receptors and methods of use
IL250536A0 (en) Chimeric antigen receptors
IL252617A0 (en) Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
IL252604B (en) Chimeric antigen receptors and methods of use
HUE056074T2 (hu) BCMA kiméra antigénreceptorok
IL249305A0 (en) Chimeric antigen receptors targeting cd-19
AU2015269219B2 (en) Mesothelin-targeted chimeric antigen receptors and uses thereof
CL2016002196A1 (es) Receptor antigénico quimérico
IL250202A0 (en) bcma chimeric antigen receptors
ZA201703471B (en) Anti-cldn chimeric antigen receptors and methods of use
LT3333191T (lt) Anti-c10orf54 antikūnai ir jų panaudojimas
PL3230310T3 (pl) Chimeryczne receptory antygenowe anty-cd70
IL263627A (en) Chimeric antigen receptors (cars) specific for muc1 and methods for their use
DK3169703T4 (da) Kimær antigenreceptor og anvendelse deraf
IL252929B (en) Anti-acth antibodies from humans and their use
TH1601000713A (th) แอนทิบอดีใหม่ที่ต้าน-ตัวรับ tslp ของมนุษย์

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed